Q-omics provides the consensus-scored CALML5 profile across patient tissues and cancer cell-line models. CALML5 expression is associated with patient survival in 20 of 34 cancer types, with the highest sampling consensus in HNSC. Among the 18 cancer types available for tumor–normal comparison, CALML5 is differentially expressed in 6, with the highest sampling consensus in LUSC. Additionally, CALML5 RNA expression shows 10,081 significant gene co-expression associations, with the highest sampling consensus in TGCT. Together, these results highlight HNSC, LUSC, and TGCT as cancer lineages where CALML5 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for CALML5 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes CALML5 survival associations across molecular data types. CALML5 RNA expression shows survival associations in the most cancer types (20), followed by mutation status (2) and mass-spec protein abundance (3). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible CALML5 RNA expression–survival associations across cancer types. High CALML5 expression shows unfavorable associations in SKCM, LIHC, READ and LUAD, but favorable associations in HNSC and CESC. The HNSC Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p < 0.001). Together, the overview and detailed table identify HNSC as the clearest survival context for CALML5 RNA expression.
This table summarizes CALML5 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 6, while mass-spec protein shows differences in 3. The strongest signals are observed in LUSC for RNA and LSCC for protein.
This table ranks reproducible tumor–normal expression differences for CALML5. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. CALML5 shows higher tumor expression in LUSC, BLCA, UCEC, PAAD, CHOL and LUAD. The LUSC box plot shows higher CALML5 RNA expression in tumor versus normal tissue (log2 FC = +3.863, t-test p < 0.001).
This table shows molecular features associated with CALML5 in patient tissues and cancer cell lines. In patient samples, CALML5 shows the broadest associations at the RNA and protein expression levels, with TGCT recurring as the lineage with the largest associated feature set. In cancer cell lines, CALML5 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in BLOOD_Leukemia, while CRISPR and shRNA rows add functional-dependency signals in BREAST and LARGE_INTESTINE.
